新型保护性β-内酰胺类抗生素的延长与持续输注:叙述性综述
本叙述性综述汇总了新型β-内酰胺/β-内酰胺酶抑制剂复方(头孢洛扎-他唑巴坦、头孢他啶-阿维巴坦、美罗培南-法硼巴坦、亚胺培南-西司他丁-瑞来巴坦)延长或持续输注的药理学与临床数据。药效学目标为游离药物浓度约四倍最低抑菌浓度的时间最大化,以优化杀菌并支持抗菌药物管理。综述还讨论了住院及门诊肠外抗菌治疗中的应用、未来展望与当前局限。
要点
- 延长或持续输注可提高游离药物浓度超MIC时间占比,优化杀菌效果。
- 药效学目标包括达到突变预防浓度,助力多重耐药菌感染管理。
- 新型βL/βLI复方的延长输注在特定场景和人群中有 promising 证据。
核心结论
- 延长或持续输注新型保护性β-内酰胺类可优化药效学目标,但仍是未充分利用的资源。
研究设计与样本
- 叙述性综述,汇总药代动力学/药效学研究、临床前与真实世界证据。
主要发现
- 药代动力学/药效学研究支持延长输注以提高达到最大杀菌活性的概率。
- 延长输注有助于达到突变预防浓度,支持多重耐药菌感染管理。
- 新型βL/βLI复方在特定场景和临床人群中显示延长输注的 promising 作用。
关键数值与推荐
- 药效学目标为给药间期内游离药物浓度约为最低抑菌浓度的四倍的时间最长。
临床怎么用
- 在抗菌药物管理框架下,对多重耐药革兰阴性菌感染可考虑延长输注新型βL/βLI复方。
- 住院和门诊肠外抗菌治疗中可应用延长输注策略。
局限性
- 延长输注仍是被低估和未充分利用的给药方式。
- 综述指出了当前局限与未来展望,但未提供具体数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Consolidated data from pharmacokinetic and pharmacodynamic studies support the administration of β-lactam antibiotics in prolonged infusion (i.e., extended or continuous) to optimize therapeutic efficacy by increasing the probability of attaining maximal bactericidal activity. This is the longest possible time during which the free drug concentrations are approximately four-fold the minimum inhibitory concentration between dosing intervals. In the context of antimicrobial stewardship strategies, achieving aggressive pharmacokinetic and pharmacodynamic targets is an important tool in the management of multi-drug resistant (MDR) bacterial infections and in the attainment of mutant preventing concentrations. However, prolonged infusion remains an unexploited resource. Novel β-lactam/β-lactamase inhibitor (βL/βLI) combinations (ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-cilastatin-relebactam) have been released in recent years to face the emerging challenge of MDR Gram-negative bacteria. Pre-clinical and real-life evidence has confirmed the promising role of prolonged infusion of these molecules in specific settings and clinical populations. In this narrative review we have summarized available pharmacological and clinical data, future perspectives, and current limitations of prolonged infusion of the novel protected β-lactams, their application in hospital settings and in the context of outpatient parenteral antimicrobial therapy.
引用
- Venuti F, Trunfio M, Martson AG, et al. Extended and Continuous Infusion of Novel Protected β-Lactam Antibiotics: A Narrative Review. Drugs. 2023. PMID: 37314633. doi:10.1007/s40265-023-01893-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。